Literature DB >> 7868909

Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.

V Casini-Raggi1, L Kam, Y J Chong, C Fiocchi, T T Pizarro, F Cominelli.   

Abstract

The etiology and pathogenesis of inflammatory bowel disease (IBD) are unknown. Increasing evidence supports the theory that chronic IBD is the result of dysfunctional immunoregulation manifested by an inappropriate production of mucosal cytokines. The aim of the present study was to test the hypothesis that a specific mucosal imbalance of IL-1 and IL-1 receptor antagonist (IL-1ra) production plays an important role in the perpetuation and chronicity of intestinal inflammation. Total IL-1, IL-1ra, and the IL-1ra/IL-1 ratio were measured in freshly isolated intestinal mucosal cells, as well as in mucosal biopsies obtained from control, Crohn's disease, and ulcerative colitis patients. IL-1 alpha, IL-1 beta, and IL-1 ra were measured by specific non-cross-reacting radioimmunoassays and ELISA. A markedly significant decrease in the intestinal mucosal IL-1ra/IL-1 ratio was found in both Crohn's disease and ulcerative colitis patients when compared with control subjects (p < 0.01). The IL-1ra/IL-1 ratio correlated closely with the clinical severity of disease (r = -0.7846, p < 0.001). Furthermore, the observed decrease in the IL-1ra/IL-1 ratio was specific for IBD because a decreased IL-1ra/IL-1 ratio was not found in patients with self-limiting colitis. These results support the hypothesis that an imbalance between IL-1 and IL-1ra production is of pathogenic importance in chronic inflammatory diseases, including IBD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7868909

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  128 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation.

Authors:  C Fiocchi
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Gut lavage IgG and interleukin 1 receptor antagonist:interleukin 1 beta ratio as markers of intestinal inflammation in children with inflammatory bowel disease.

Authors:  R Troncone; N Caputo; A Campanozzi; M Cucciardi; V Esposito; R Russo; B De Vizia; L Greco; S Cucchiara
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 4.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

5.  Ulcerative colitis associated with aplastic anemia.

Authors:  Hiroshi Kishikawa; Jiro Nishida; Masaru Nakano; Erika Hirano; Tetsuo Morishita; Hiromasa Ishii
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

Review 6.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

7.  The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.

Authors:  Tomer Adar; Shimon Shteingart; Ami Ben-Ya'acov; Ariella Bar-Gill Shitrit; Dan M Livovsky; Shimrit Shmorak; Mahmud Mahamid; Bernardo Melamud; Fiona Vernea; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

Review 8.  Cytokine polymorphisms in silicosis and other pneumoconioses.

Authors:  Berran Yucesoy; Val Vallyathan; Douglas P Landsittel; Petia Simeonova; Michael I Luster
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

9.  Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases.

Authors:  A Nemetz; M Tóth; M A García-González; T Zágoni; J Fehér; A S Peña; Z Tulassay
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 10.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.